R-Verapamil - Center Laboratories

Drug Profile

R-Verapamil - Center Laboratories

Alternative Names: Arverapamil - Center Laboratories; CS 02

Latest Information Update: 18 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Center Laboratories
  • Class Antiarrhythmics; Antihypertensives; Antineoplastics; Irritable bowel syndrome therapies; Ischaemic heart disorder therapies; Nitriles; Phenethylamines; Small molecules
  • Mechanism of Action Calcium channel antagonists; Melatonin MT1 receptor modulators; Somatostatin receptor 2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Cluster headache; Type 2 diabetes mellitus

Most Recent Events

  • 01 Mar 2018 Center Laboratories terminates phase II trial in Cluster headache (Prevention) in United Kingdom (PO) (NCT02209155)
  • 01 Oct 2017 Phase-II clinical trials in Type-2 diabetes mellitus (Combination therapy) in Taiwan and USA (PO) (NCT03308695)
  • 10 Oct 2016 R-Verapamil is still in phase II trials for Cluster headache in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top